Use of recombinant human erythropoietin as adjuvant therapy for blood banking for autotransfusion in dogs.
Recombinant human erythropoietin (rhEPO) has been assessed for its potential value as an adjuvant in the banking of blood for autotransfusion in dogs. Twelve normal adult dogs were assigned to three groups (saline, iron, and iron plus EPO groups). On day 0, day 3, and immediately after each autologous blood donation, the first group received normal saline as a placebo, the second group received 4.1 mgkg-1 of iron (iron chondroitin sulphate), and the third group received 600 IU kg-1 of rhEPO in combination with 4.1 mgkg-1 of iron. Blood for autologous donation equivalent to 10 mL kg-1 was collected from each dog on days 7 and 10. The blood was retransfused on day 14 during the removal of an equal volume of blood and the effect of the autotransfusion evaluated on day 17. After the autologous blood donation, a marked decrease in haematocrit occurred in the saline and iron groups. In contrast, the haematocrit remained virtually unchanged in the iron plus EPO group indicating the therapeutic effect of rhEPO. The iron plus EPO group also maintained a high haematocrit after blood collection if they had been autotransfused first. It was concluded that rhEPO is a valuable adjuvant in canine blood banking for autotransfusion.